Get the Stockscreener App
4.685
0.11%
0.005
Passage Bio Inc stock is traded at $4.685, with a volume of 13,815.
It is up +0.11% in the last 24 hours and down -16.64% over the past month.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
See More
Previous Close:
$4.68
Open:
$4.48
24h Volume:
13,815
Relative Volume:
0.13
Market Cap:
$15.05M
Revenue:
-
Net Income/Loss:
$-37.68M
P/E Ratio:
-0.3958
EPS:
-11.8364
Net Cash Flow:
$-30.65M
1W Performance:
-3.40%
1M Performance:
-16.64%
6M Performance:
-74.62%
1Y Performance:
+915.83%
1-Day Range:
$4.48
$4.74
1-Week Range:
$4.42
$4.99
52-Week Range:
$0.3502
$20.00
Passage Bio Inc Stock (PASG) Company Profile
Name
Passage Bio Inc
Sector
Industry
Phone
(267) 866-0312
Address
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
4.685 | 15.68M | 0 | -37.68M | -30.65M | -11.84 |
VRTX
Vertex Pharmaceuticals Inc
|
527.99 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
647.54 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
926.19 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.63 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.17 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Apr-21-26 | Downgrade | TD Cowen | Buy → Hold |
| Apr-21-26 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-31-26 | Initiated | Oppenheimer | Outperform |
| Feb-10-26 | Resumed | Chardan Capital Markets | Buy |
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Sep-03-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-08-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-19-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-01-21 | Initiated | Raymond James | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Mar-04-21 | Upgrade | Goldman | Neutral → Buy |
| Feb-04-21 | Initiated | Guggenheim | Buy |
| Jan-25-21 | Initiated | Wedbush | Outperform |
| Jan-04-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Aug-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-25-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-25-20 | Initiated | Chardan Capital Markets | Buy |
| Mar-24-20 | Initiated | Cowen | Outperform |
| Mar-24-20 | Initiated | Goldman | Buy |
| Mar-24-20 | Initiated | JP Morgan | Overweight |
View All
Passage Bio Inc Stock (PASG) Latest News
Latham & Watkins Advises Remix Therapeutics in Merger With Passage Bio - Legal Desire Media and Insights
Passage Bio (PASG) holder adds 50,055 shares in open-market buy - Stock Titan
Passage Bio to Merge With Remix in Deal Backed by $100 Million Financing - MyChesCo
Passage Bio, Inc. Actuals & Estimates (NASDAQ:PASG) - TradingView
Enterprise value to EBIT forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Layoff Tracker: Biogen axes ‘small number’ of Apellis roles after $5.6B buy - BioSpace
Price to sales forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Price to book forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Price to earnings forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Passage Bio, Inc. Actuals & Estimates (BOATS:PASG) - TradingView
Baselake Partners (PASG) reports 235,058 shares, 7.3% ownership - Stock Titan
Remix Therapeutics secures $100M and a reverse merger - The Business Journals
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Remix to go public in reverse merger with once high-flying Passage Bio - BioPharma Dive
PASG Forecast — Price Target — Prediction for 2027 - TradingView
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Remix to enter Nasdaq through Passage Bio reverse merger - The Pharma Letter
Passage Bio and Remix Therapeutics Announce Merger to Advance RNA-Targeted Cancer Therapies with $100M Financing – Minichart - Minichart
SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today - TradingView
SGMOQ Stock Price and Chart — OTC:SGMOQ - TradingView
PASG Stock Slumps 16% After-Hours — What’s Driving The Selloff? - Asianet Newsable
Stocks to Watch: Micron, ARS Pharmaceuticals, MillerKnoll, Passage Bio - Moomoo
Passage Bio Shares Slide on Merger With Remix Therapeutics - Moomoo
Passage Bio And Remix Therapeutics Announce Merger Agreement - TradingView
Passage Bio (PASG) Slides 3.9% as Momentum Falters Near Key SupportWave Truncation - dars.gov.et
Passage Bio (PASG) to merge with Remix; Remix private placement tops $100M - Stock Titan
Passage Bio to merge with Remix Therapeutics in all-stock deal - Investing.com
9 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Passage Bio to Merge With Remix Therapeutics; Remix Valued at $226M, $100M Financing - TradingView
Passage Bio (PASG) to combine with Remix; Remix valued at $226M, $100M raise - Stock Titan
Passage Bio | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactionsmoomoo - Moomoo
Remix Therapeutics to reverse-merge with Passage Bio (PASG) and raise $100M - Stock Titan
Press Release: Passage Bio and Remix Therapeutics Announce Merger Agreement - Moomoo
PASG Stock Slumps 16% After-HoursWhat's Driving The Selloff? - Mena FN
Remix Therapeutics, Inc. entered into a definitive merger agreement to acquire Passage Bio, Inc. in a reverse merger transaction for approximately $230 million. - marketscreener.com
Passage Bio Inc (PASG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Passage Bio Inc (PASG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Passage Bio Inc (PASG) Valuation: PE, PB & Fair Value Analysis - TradingKey
Passage Bio Inc (PASG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Passage Bio Inc (PASG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Passage Bio Inc (PASG) Institutional Confidence - TradingKey
Passage Bio Inc (PASG) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Passage Bio Inc (PASG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Passage Bio Inc (PASG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sea Limited’s Shopee Order Growth Reinforces E-Commerce MomentumEarnings Momentum Score - newsline.com
PRS Q1 2026 Earnings: Solid EPS Beat Driven by Core OperationsEarnings Deceleration Risk - newsline.com
Passage Bio Inc. (PASG) Surges Over 9% as Biotech Stock Tests Key ResistanceEarnings Quality Factor - newsline.com
Gartner (IT) Q1 2026 Earnings: EPS Surprises to the Upside Despite Modest Stock PullbackRevenue Recognition Risk - newsline.com
Fierce Biotech Layoff Tracker 2026: Genentech trims R&D; Neumora cuts 35% - Fierce Biotech
Guggenheim Downgrades Passage Bio(PASG.US) to Hold Rating - Moomoo
Passage Bio (PASG) Downgraded to Neutral as Strategic Review Ini - GuruFocus
Passage Bio Inc Stock (PASG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Passage Bio Inc Stock (PASG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chou William | PRESIDENT AND CEO |
Jan 08 '26 |
Sale |
18.44 |
4,076 |
75,159 |
6,524 |
| Borthwick Kathleen | CFO |
Jan 08 '26 |
Sale |
18.44 |
2,062 |
38,022 |
5,402 |
0.72%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):